ETF profile for iShares Neuroscience And Healthcare ETF (IBRN) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
IBRN ETF Profile
| Family: |
Blackrock (iShares) |
| Name: |
iShares Neuroscience and Healthcare ETF |
|
|
| Inception Date: |
24-Aug-2022 |
| Termination Date: |
|
| Investment Objective: |
The iShares Neuroscience and Healthcare ETF seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. Proviedes exposure to global stocks involved in the research, development and treatment of neurological disorders. |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| BIOGEN |
BIIB |
5.3551% |
| NEUROCRINE BIOSCIENCES |
NBIX |
4.9868% |
| ALKERMES |
ALKS |
4.6936% |
| PTC THERAPEUTICS |
PTCT |
4.6122% |
| EDGEWISE THERAPEUTICS |
EWTX |
4.3758% |
| ARGENX SE ADR |
ARGX |
4.2112% |
| SK BIOPHARMACEUTICALS LTD |
326030 |
4.0637% |
| SCHOLAR ROCK HOLDING |
SRRK |
3.9927% |
| AXOGEN |
AXGN |
3.9086% |
| DIANTHUS THERAPEUTICS |
DNTH |
3.7216% |
|
Top 10 Holdings Weight: |
43.9% |
| Number of Holdings: |
80 |
| Shares Outstanding: |
200,000 |
| Total Net Assets: |
6,578,800 |
| NAV: |
32.75 |
| Net Expense Ratio: |
0.47% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
|
| Region: |
|
| Strategy: |
|
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
|
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Broad Market / Multi-Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
|
| Is Currency Hedged: |
No |
| US or Ex-US: |
Global |
